Literature DB >> 3907286

One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis.

K Holmgren, G Andersson, B Fagrell, H Johnsson, B Ljungberg, E Nilsson, S Wilhelmsson, S Zetterquist.   

Abstract

The length of time for which deep vein thrombosis (DVT) should be treated with oral anticoagulants (OA) is controversial. In this study, 135 patients with symptomatic first period DVT (83% with proximal DVT) were randomly allocated to OA for one or six months. The diagnosis of initial and recurrent DVT was confirmed by phlebography or plethysmography and thermography, or by a combination of all these methods. Pulmonary emboli were confirmed by lung scans or at autopsy. The patients were followed for at least one year. One patient had to discontinue OA prematurely because of haemorrhage. Seventeen patients left the project for other reasons, ten during and seven after therapy; in one of these DVT recurred. The recurrence rate during the first year was high (17% symptomatic recurrences) irrespective of whether OA had been given for one or six months.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3907286     DOI: 10.1111/j.0954-6820.1985.tb06125.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  19 in total

Review 1.  Anticoagulation in patients with thromboembolic disease.

Authors:  R C Tait
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

2.  Safety of anticoagulation in the elderly: reasons for discontinuing therapy.

Authors:  P A O'Neill; D Crossley; D A Taberner; D S Fairweather
Journal:  Postgrad Med J       Date:  1992-10       Impact factor: 2.401

Review 3.  Duration of anticoagulant therapy in pediatric venous thromboembolism: Current approaches and updates from randomized controlled trials.

Authors:  Cristina Tarango; Sam Schulman; Marisol Betensky; Neil A Goldenberg
Journal:  Expert Rev Hematol       Date:  2017-12-17       Impact factor: 2.929

Review 4.  Anticoagulant drugs in the elderly: the risks usually outweight the benefits.

Authors:  P J Scott
Journal:  BMJ       Date:  1988-11-12

Review 5.  Anticoagulants in venous thromboembolism.

Authors:  A Fennerty; I A Campbell; P A Routledge
Journal:  BMJ       Date:  1988-11-19

Review 6.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

7.  Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial.

Authors:  I A Campbell; D P Bentley; R J Prescott; P A Routledge; H G M Shetty; I J Williamson
Journal:  BMJ       Date:  2007-02-08

8.  Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism.

Authors:  David Keith Cundiff
Journal:  Medscape J Med       Date:  2008-11-11

Review 9.  Heparin therapy. Regimens and treatment considerations.

Authors:  T M Hyers
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 10.  Safety of treatment with oral anticoagulants in the elderly. A systematic review.

Authors:  B A Hutten; A W Lensing; R A Kraaijenhagen; M H Prins
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.